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Abstract We conducted a cross-sectional study in 448 HIV
positive patients attending five European outpatient clinics to
determine prevalence of and factors associated with neu-
rocognitive impairment (NCI) using computerized and pen-
and-paper neuropsychological tests. NCI was defined as a
normalized Z score B-1 in at least 2 out of 5 cognitive
domains. Participants’ mean age was 45.8 years; 84% male;
87%white; 56% university educated; median CD4 count 550
cells/mm3; 89% on antiretroviral therapy. 156 (35%) partici-
pants hadNCI, amongwhom26 (17%; 5.8%overall) reported
a decline in activities of daily living. Prevalence of NCI was
lower in those always able to afford basic needs (adjusted
prevalence ratio [aPR] 0.71, 95% confidence interval [CI]
0.54–0.94) or with a university education (aPR 0.72, 95% CI
0.54–0.97) and higher in those with severe depressive symp-
toms (aPR 1.53, 95% CI 1.09–2.14) or a significant comorbid
condition (aPR 1.40, 95% CI 1.03–1.90).
Resumen Reportamos un estudio de tipo corte transversal
que incluye 448 pacientes VIH seropositivos vistos en
cinco clı´nicas especializadas en Europa con el objetivo de
medir la prevalencia del trastorno neurocognitivo asociado
al VIH (NCI por sus siglas en ingle´s) y los factores de
riesgo asociados a e´ste. Se usaron pruebas neuropsi-
colo´gicas computarizadas y en papel para determinar la
presencia de NCI, definido como puntuacio´n Z B 1 en al
menos 2 de los 5 dominios cognitivos evaluados. La media
de edad de los pacientes fue 45,8 an˜os, 84% eran hombres,
87% blancos y 56% tenı´an educacio´n universitaria. La
media de CD4 fue de 550 cel/mm3 y 89% de los pacientes
recibı´an terapia antiretroviral. Un total de 156 (35%) par-
ticipantes tenı´an NCI, de los cuales 26 (17%, 5,8% de la
poblacio´n de estudio) reportaron deterioro en actividades
de la vida diaria. La prevalencia de NCI fue menor en
participantes capaces de cubrir sus necesidades ba´sicas
(Razo´n de prevalencia ajustada [aPR] 0,71; Intervalo de
confianza del 95% [95% CI] 0,54-0,94) o con educacio´n
universitaria (aPR 0,72; 95%CI 0,54-0,97) pero fue mayor
en aquellos con sı´ntomas de depresio´n severa (aPR 1,53;
95%CI 1,09-2,14) o alguna comorbilidad importante (aPR
1,40; 95%CI 1,03-1,90).
Keywords HIV  Prevalence  HIV dementia 
Neuropsychological assessment  MCI (mild cognitive
impairment)  Activities of daily living
Introduction
HIV-1 can cause neurological disease, but severe impair-
ment is rare in HIV positive (HIV?) patients with access to
antiretroviral therapy (ART) [1]. A variety of estimates of
prevalence of milder neurocognitive impairment (NCI)
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have been reported in HIV? patients, exceeding 50% in
studies from Western Europe and North America [2–4], but
as low as 19% in other studies using broadly similar neu-
ropsychological (NP) definitions [5, 6]. Estimates may vary
because of differences in the characteristics of study pop-
ulations. Most studies have focused on a particular setting
(such as clinical trial participants [5, 7, 8], a single country
[2–7, 9], or a specific patient group [6, 10]), and many
studies have specifically excluded participants with
potentially confounding conditions, detectable viral load or
low CD4 count [2, 5, 7, 9, 11]. There is a need to study
more diverse HIV ? populations inclusive of those with
typical comorbid conditions to clarify the effects of clini-
cal, psychological and social variables as risk factors. As
well as differences between study populations, differences
in assessment method may lead to variations in results.
Despite efforts to standardize definitions of HIV-associated
NCI, for example with the ‘‘Frascati criteria’’ [12] or with a
threshold in global deficit score (GDS) [13], there may be
important differences between measuring instruments. The
use of computerized neuropsychological testing batteries is
one method that may provide stable and cross-cultural
measures of cognitive function [14–17].
Our primary aim was to estimate prevalence of NCI,
using mainly computerized assessment, in HIV? outpa-
tient samples in four European countries (UK, Italy, Den-
mark and Belarus). Our secondary aim was to assess
associations of clinical and social variables with NCI, in
order to identify potentially modifiable risk factors for NCI
in HIV? patients.
Methods
Participants
CIPHER is a five-center European study of HIV? outpa-
tients (two clinics in London, UK, and one clinic in each
of: Copenhagen, Denmark; Minsk, Belarus; Rome, Italy).
Participants were sampled opportunistically at the time of
routine outpatient attendance from May 2011 to January
2013. Participants had to be at least 18 years of age and
able to give consent and complete study procedures. They
were recruited regardless of symptoms, treatment and
comorbidities.
Neurocognitive and Functional Status Assessments
The study used Cogstate, software adapted from standard
NP tasks for assessment of multiple cognitive domains
(http://cogstate.com/academic-2/measurement-of-cognition)
[18–20], and two pen-and-paper NP tests. The self-com-
pleted tests are mainly non-language-based and the stimuli
vary randomly between assessments, reducing the influence
of cultural, educational, and practice effects. Computerized
NP testing is widespread in research and clinical practice,
and several studies have used Cogstate in HIV? patients in
Anglophone countries [5, 14, 15, 21–24], with some work
demonstrating good construct validity and correlation with
traditional pen-and-paper NP batteries [14, 15, 21]. Ten
tests were conducted; these were organized into five
domains: psychomotor speed (detection and identification
tests); verbal memory (Shopping List learning and recall
tests); executive function (Groton Maze learning and recall
tests; these tests also assess visuospatial learning and
memory); working memory (One-Back speed and accuracy
tests); verbal fluency (two pen-and-paper tests: controlled
oral word association test [COWAT] and category fluency
test [CFT]). The battery was designed to be reliable and
standardized across sites, and a single researcher conducted
the same training for assessors at all sites. Testing included
a full practice run, which was not scored, on the same day as
the main assessment. The practice and main assessment
took around 90 min in total, not including rest breaks.
Analysis of serial testing with Cogstate suggests an early
practice effect between the first and second runs, and sub-
sequent stabilization even with short time intervals [25].
The use of a practice run prior to the main assessment
optimizes performance while minimizing practice effects
and is recommended by the manufacturer’s Research
Manual.
Functional status was measured using a self-completed
questionnaire, the Modified Lawton & Brody Instrumental
Activities of Daily Living Scale, which required partici-
pants to indicate their current and best ever level of func-
tion on 16 activities of daily living (ADL) such as cooking,
shopping, managing finances and taking medication.
Where decline had occurred, participants were asked to
record the perceived cause as physical, cognitive, or both.
The questionnaire has been used in large published studies
of HAND [3] and shows good correlation with the
Karnofsky score and performance-based measures of
function [26].
Other Data Collection
All participants were attending clinic regularly for HIV
care. They completed a questionnaire including demo-
graphic, socio-economic and HIV-related factors, depres-
sion and anxiety symptom scales (PHQ-9 and GAD-7),
medical history, and recreational drug and alcohol use.
PHQ-9 scores were graded as: 0–4, none/minimal depres-
sion; 5–9, mild; 10–14, moderate; 15–19, moderate-severe;
20–27, severe. GAD-7 scores were graded as: 0–4, none/
minimal anxiety; 5–9, mild; 10–14, moderate; 15–21,
severe. Problem drinking was defined by the modified
1574 AIDS Behav (2018) 22:1573–1583
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(two-question) AUDIT-C questionnaire: a positive score
was C5 points for men or C4 points for women. Financial
hardship was assessed by the question ‘‘Do you have
enough money to cover your basic needs?’’ Respondents
could answer always, most of the time, some of the time, or
no, and any answer other than ‘‘always’’ was considered to
be positive for this analysis. Additional information col-
lected from clinical and laboratory records at the time of
assessment included HIV viral load (VL), CD4 count, ART
use, AIDS-defining illnesses, lipids, glucose, liver function
tests, and details of neurological, cardiovascular and psy-
chiatric comorbidities. Hepatitis C virus (HCV) status was
defined by the most recent HCV RNA assay, or the most
recent antibody result in the absence an RNA result.
Measures and Definitions
Each cognitive test score was converted to an age-, sex-,
and education-standardized Z-score using normative means
and SD. Normative general population data for the com-
puterized tests were provided by Cogstate from Europe,
United States of America, South East Asia, Australia and
New Zealand, stratified by age group (18–34, 35–50, and
51? years; minimum cell size n = 145), sex (157 female,
377 male), and education (university/further education,
n = 243, or secondary school, n = 291). Exclusion criteria
for the normative data included any clinically significant
neurological, psychiatric or other disease, impaired visual
or auditory acuity, and routine use of neurologically active
medications, and assessments had been conducted in the
individual’s first language. All or subsets of this normative
data had been used previously to classify cognitive func-
tion in HIV? adults [5, 15, 21, 22, 24]. Published age-,
sex- and education-stratified norms were used for the
COWAT and CFT [27, 28].
Scores for each of the five domains were categorized as
severely impaired (Z B -2), mildly impaired (-2\ Z B
-1), or normal (Z[-1). NCI was defined as at least mild
impairment in at least 2 out of 5 cognitive domains. We
excluded participants with fewer than 5 gradable domains. In
addition, we defined grades of impairment, based on Frascati
criteria: HIV-Associated Dementia (HAD), severely
impaired in at least 2 cognitive domains with significant
functional decline (decline in C4 ADL, reported by the
patient to result from cognitive difficulties); Mild Neu-
rocognitive Disorder (MND), NCI with at least mild func-
tional decline (defined as decline in 2–3 ADL) but not
meeting criteria for HAD; Asymptomatic Neurocognitive
Impairment (ANI), NCI with no functional decline (maxi-
mum of one ADL affected). Strict application of the Frascati
criteria demands that there is no evidence of a pre-existing
cause for the impairment and suggests that assessment be
revisited when the comorbid condition has resolved.
Therefore, participants with any of a pre-specified list of
conditions were noted but not excluded from analysis. The
full list of conditions was published as an appendix to the
original criteria [12] and includes depressive disorders, his-
torical traumatic brain injury, developmental disabilities,
alcohol and substance use disorders, certain HIV-related and
non-HIV-related neurologic conditions, and systemic dis-
ease likely to affect cognition (including HCV infection).
We adopted the nomenclature used by theCHARTERgroup,
where contributing conditions were those deemed to have
potential for mild cognitive impairment, while confounding
conditions were those likely to have a substantial effect on
cognitive function [3].
Statistical Analyses
Participant characteristics were compared between countries
using the exact test for categorical variables, ANOVA for
normally-distributed continuous variables, and the Kruskal–
Wallis test for non-normally-distributed continuous variables
and ordinal scales. Prevalence of NCI with 95% confidence
intervals (CI) was calculated. Modified Poisson regression
analyses were used to assess unadjusted and adjusted preva-
lence ratios for factors associated with NCI, with CIs calcu-
lated from robust standard errors [29]. We did not use the
Frascati criteria for these analyses because we wished to
estimate the associations with factors that would affect the
outcome measure (such as depression and confounding con-
ditions). The associations of five variables with NCI were
estimated (age, sex, education, and presence of confounding
and contributing conditions). Then individual analyses of
other clinical and psychosocial variables were performed,
with adjustment for age, sex, education and confounding
conditions. Finally, all variables found to be associated with
NCI (P B 0.1) in either of the earlier models were incorpo-
rated into a multivariable analysis. Because depression and
anxiety symptom scores were highly collinear, only the
strongerof these twovariableswas included in thefinalmodel.
To explore which cognitive domains were driving associ-
ations between risk factors and the global measure of NCI,
factors associated with the raw scores on each neurocognitive
test were assessed in separate models. In these models, the
main variables of age, sex, education and confounding con-
ditions and all variables noted to be related to global NCI in
subsequent analyses were included in a multivariable model.
Results
Study Population
Of 486 patients recruited, 448 (92%) completed both
practice and baseline assessments (London, 292 [65%];
AIDS Behav (2018) 22:1573–1583 1575
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Rome 90 [20%]; Copenhagen 42 [9.4%]; Minsk 24
[5.4%]). The remainder were excluded from further anal-
ysis: 15 participants who only completed the practice
assessment and 23 who did not complete all five cognitive
domains. The sample was 87% white, 84% male, and mean
45.8 years of age (SD 9.6). 89% were on ART, of whom
91% had VL\ 50 copies/mL (81% overall). The sites
differed significantly on many characteristics (Table 1):
participants in Minsk had the youngest age, lowest CD4
count, lowest proportion undetectable on ART and shortest
time since HIV diagnosis, while Rome had the lowest
proportion of university-educated participants, and London
had the highest proportion of non-white participants and
migrants. Rome and Minsk had a higher proportion of
injection drug users, while problem drinking and recent
recreational non-injection drug use were particularly
prevalent in London. Moderate to severe depressive
symptoms were present in a quarter of patients, and anxiety
symptoms of similar severity in a fifth. Antidepressants or
psychotherapy were being prescribed to 37% of those with
moderate/severe symptoms and 10% of those with no or
mild symptoms (16% overall).
Prevalence of NCI and Functional Impairment
Of 448 participants, 156 (35%) met the definition of NCI
(at least mild impairment in at least 2 out of 5 cognitive
domains). Of those with NCI, 39 (25%) had confounding
conditions, the most common being major substance use
disorders (n = 22), AIDS-defining conditions of the CNS
(n = 8), and severe ongoing depression (n = 12). Of 292
patients not meeting the definition of NCI, 42 (14%) had
confounding conditions, including 27 with major substance
use, 2 with AIDS-defining CNS conditions, and 9 with
severe depression. The spectrum of severity of NCI com-
prised four (0.9% of the overall study sample; 1.1% of
those without confounding conditions) with HAD, 22
(4.9%; 6.0%) with MND, and 91 (20%; 25%) with ANI.
Seventy-five (17%) patients reported a decline in ADL
caused by cognitive problems, although just over half of
these (42; 56%) did not meet the definition of NCI. Seventy
patients (16%) reported a decline in ADL caused by
physical problems, and there was significant overlap
between self-perceived physical and cognitive impairment,
with 42 patients attributing their decline in function to both
factors.
Clinical, Social and Psychological Factors
Associated with Prevalence of NCI
Analyses of the main explanatory variables are shown in
Table 2. The presence of a confounding condition (preva-
lence ratio [PR] 1.51, 95% CI 1.15–1.98), being
heterosexual and male (PR 2.03, 95% CI 1.53–2.69) or
female (PR 1.44, 95% CI 1.04–2.00), and having no uni-
versity education (PR 1.75, 95% CI 1.35–2.27) were
associated with NCI, there was a weak trend associated
with increasing age (PR 1.13 per decade, 95% CI
1.00–1.29).
Table 3 shows partially and fully-adjusted analyses.
University education (adjusted PR [aPR] 0.72, 95% CI
0.54–0.97) and always being able to afford basic needs
(aPR 0.71, 95% CI 0.54–0.94) were associated with a lower
prevalence of NCI. Paradoxically, problem alcohol con-
sumption was also associated with a lower prevalence of
NCI (aPR 0.68, 95% CI 0.46–1.00). Being assessed at the
Rome study site (aPR 1.85, 95% CI 1.31–2.62), a con-
founding condition (aPR 1.40, 95% CI 1.03–1.90), and
severe depressive symptoms (aPR 1.53, 95% CI 1.09–2.14)
were associated with a higher prevalence of NCI. There
was weak evidence for higher prevalence of NCI among
patients with a longer time since HIV diagnosis (aPR 1.09
per ?5 years, 95% CI 0.99–1.19) and non-white ethnic
groups (aPR 1.36, 95% CI 0.95–1.97). Analysis of the
effects of individual classes of recreational and prescribed
drugs found no other correlates of impaired NP function
(results not shown). In sensitivity analyses, replacing
depressive with anxiety symptoms as a factor in the model
did not produce any notable difference in the effect sizes.
Linear regression analyses with the mean Z for all tests
as a continuous dependent variable broadly identified the
same associated factor of ability to meet basic needs
(correlation coefficient [b] ? 0.31 increase in Z score, 95%
CI 0.14–0.49), and similar risk factors of duration of HIV
infection (b -0.07 per ?5 years, 95% CI -0.13 to -0.00),
non-white ethnic group (b -0.40, 95% CI -0.68 to
-0.11), and study site (b for Rome -0.52, 95% CI -0.75
to -0.29).
Sensitivity Analyses
When clinic site was removed as a covariate from the fully
adjusted Poisson model, lack of university education and
being a heterosexual male showed slightly stronger asso-
ciations with NCI, although there was little overall differ-
ence to the pattern of associations. When participants in
Italy were excluded, most adjusted estimates changed little,
but there was no longer a statistically significant effect of
being able to afford basic needs (aPR 0.77, 95% CI
0.52–1.13). To investigate the possibility that some com-
ponent of the battery was driving the high prevalence of
NCI at the Italian site, we compared each test between sites
in a linear regression model adjusted for the other impor-
tant cofactors. Participants in Rome had worse scores on
six tests encompassing four out of five cognitive domains
1576 AIDS Behav (2018) 22:1573–1583
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(choice reaction time, one-back accuracy, Groton maze
executive function task, and verbal learning and recall). On
a similar analysis of the Minsk participants, it was noted
that the mean Z scores for reaction time and choice reaction
time tasks were 1.30 and 0.75 lower than the mean for the
other three sites, whereas the Z scores for verbal learning
and recall tasks were[1 SD higher. These slower response
times and better verbal learning abilities are difficult to
explain and they were only partially attenuated by adjust-
ment for measured confounders. These effects may relate
to differences in the technical set-up or the instructions
given to participants during the Cogstate battery.
Factors Associated with Impairment of Specific
Neuropsychological Tests
The results of neuropsychological test-specific multivari-
able analyses are shown in Tables 4 and 5. Only associa-
tions with p-values of \0.005 are highlighted, to
compensate for multiple hypothesis testing. Some
notable patterns emerged. First, increasing age was asso-
ciated with two timed tasks, with verbal learning and recall,
and with the maze executive function task. Second, severe
depressive symptoms were associated with slower
responses on all timed tasks. Third, most inter-site
Table 1 Characteristics of HIV positive study participants by site
London
(n = 292)
Rome
(n = 90)
Copenhagen
(n = 42)
Minsk
(n = 24)
Total
(n = 448)
P
valuee
Age, mean (SD) 46.3 (9.0) 47.4 (8.2) 46.2 (12.3) 32.3 (6.8) 45.8 (9.6) \0.001
Male sex, % 92.5 65.6 92.9 41.7 84.4 \0.001
MSM, % 81.2 35.6 83.3 8.3 68.3 \0.001
White ethnicity, % 82.9 91.1 97.6 100 86.8 0.002
Migrant, %a 37.0 4.4 4.8 16.7 26.3 \0.001
Can always afford basic needs, % 54.1 48.9 76.2 54.2 55.1 0.025
University educated, % 57.9 35.6 78.6 62.5 55.6 \0.001
Recent psychoactive drug use, %b 38.0 14.4 14.3 8.3 29.5 \0.001
Any previous IDU, % 4.5 16.7 4.8 41.7 8.9 \0.001
Problem drinking, %c 32.5 5.7 26.2 12.5 25.2 \0.001
Depressive symptoms, %d
Moderate 14.4 6.2 4.8 9.1 11.7 \0.001f
Severe 17.2 6.2 7.1 9.1 13.8
Anxiety symptoms, %d
Moderate 15.2 11.3 4.8 4.4 12.9 0.011f
Severe 6.6 7.5 4.8 17.4 7.1
CD4 count, cells/lL, mean (SD) 597 (252) 555 (265) 659 (239) 367 (184) 582 (256) \0.001
Nadir CD4 count, median (IQR) 360 (196, 540) 211 (112, 514) 216 (140, 360) 186 (85, 234) 290 (160, 500) \0.001
Years since HIV? test, median (IQR) 9.5 (5.3, 15.4) 10.8 (5.5, 19.9) 10.3 (4.1, 19.4) 4.3 (1.6, 8.0) 9.9 (4.8, 16.2) 0.004
On ART, % 87.3 91.1 95.2 95.8 89.1 0.34
HIV RNA\50 copies/mL, % 81.2 77.8 92.9 70.8 81.0 0.09
HCV, % 13.0 18.9 4.8 29.2 14.3 0.024
ART anti-retroviral therapy, HCV hepatitis C virus, IDU intravenous drug use, IQR inter-quartile range, MSM men who have sex with men
a Defined as not born in the country of assessment
b Defined as self-reported consumption of opiates for non-medicinal use, amphetamines (including methamphetamine), cocaine, cannabis,
ketamine, gamma-hydroxybutyrate, gamma-butyrolactone, psychedelics or mephedrone in the past 3 months
c Problem drinking was defined by the modified (two-question) AUDIT-C questionnaire: a positive score was C5 points for men or C4 points for
women
d Excludes missing data (n = 12)
e P-values are derived from Chi squared or Kruskal–Wallis tests of the null hypothesis that each characteristic or variable is the same across all
four sites
f Kruskal-Wallis test comparing ordered depression or anxiety symptom scores between sites, using raw scores rather than categories
AIDS Behav (2018) 22:1573–1583 1577
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differences were apparent on language-based tasks (list
learning and recall, and verbal fluency), suggesting that
although these tests were carried out mainly in the
respondent’s language, there are important country-specific
differences in the performance of the tests. Fourth, patients
who were not always able to meet basic needs were
impaired in their performance on the CFT and COWAT.
Both of these are heavily vocabulary-dependent and this
association may indicate a relationship driven by prior
educational attainment or by current communication skills,
as well as by executive function (all of which factors could
impact on patients’ employment prospects and socioeco-
nomic status).
Discussion
In HIV? patients receiving care at five European HIV
clinics, we found that 35% fulfilled standard criteria for at
least mild NCI. Of these, a quarter had conditions that
confounded a definitive diagnosis of HAND, more than
half had no significant decline in daily function, and the
remainder (6% of the total sample) had symptomatic
HAND. Our estimates of overall prevalence and the pro-
portion with symptomatic impairment are similar to
previous estimates [2–4, 7–9], despite important differ-
ences in the target population of those studies and the
measuring instruments used. The prevalence of self-re-
ported functional decline associated with cognitive diffi-
culties was half that of measured cognitive impairment on
the NP battery, and half of the patients perceiving diffi-
culties had normal cognitive function, indicating weak
correlation between the two outcomes. The disconnect
between objective function and patients’ lived experiences
is the subject of a recent study, which concluded that
‘‘patient identification of physical versus cognitive causes
is poorly associated with objective criteria’’ [30]. These
observations have important implications for classification
of HAND in research studies and clinical practice. They
also lead to concerns about whether a diagnosis of
asymptomatic NCI creates unnecessary anxiety or, as some
data suggest [31, 32], heralds future decline.
Limitations to the Frascati criteria, CIPHER study
methodology and Cogstate have been discussed in our
earlier report on MSM in the UK [23]. In the current
analysis, we lacked an HIV-negative control group, and
although the normative population data were derived from
a healthy sample, we cannot determine whether the high
prevalence of NCI is a true effect of HIV infection. Cog-
state’s own control data are limited by their origin in an
Table 2 Unadjusted
associations of age, sex,
education and comorbid
conditions on the prevalence of
neurocognitive impairment a
Variable n (%) impaired Prevalence ratio (95% CI) P
Age, years
Under 35 18/71 (25.4) 1
35–50 91/246 (37.0) 1.46 (0.95–2.25)
51–59 35/104 (33.7) 1.33 (0.82–2.15)
60? 12/27 (44.4) 1.75 (0.98–3.14)
Per ?10 years 1.13 (1.00–1.29) 0.056
Sexual orientation and gender
MSM 91/317 (28.7) 1
Heterosexual men 36/61 (59.0) 2.03 (1.53–2.69) \0.001
Women (all) 29/70 (41.4) 1.44 (1.04–2.00) 0.029
University educated
No 91/199 (45.7) 1
Yes 65/249 (26.1) 0.57 (0.44–0.74) \0.001
Confounding conditionb
No 117/367 (31.9) 1
Yes 39/81 (48.2) 1.51 (1.15–1.98) 0.003
Contributing conditionb
No 131/385 (34.0) 1
Yes 25/63 (39.7) 1.17 (0.83–1.63) 0.37
CI confidence interval
a Neurocognitive impairment was defined as s z B -1 in at least 2 out of 5 cognitive domains
b Confounding and contributing conditions as defined in published criteria for HIV-associated neurocog-
nitive disorders (12)
1578 AIDS Behav (2018) 22:1573–1583
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Table 3 Adjusted associations of psychosocial and clinical variables with prevalence of neurocognitive impairment a
Variable PR (CI), partially-adjustedb P PR (CI), fully-adjustedb P
Age, per ?10 years 1.11 (0.97–1.30) 0.12 1.03 (0.87–1.21) 0.75
University education 0.63 (0.49–0.82) 0.001 0.72 (0.54–0.97) 0.028
Confounding condition 1.56 (1.19–2.04) 0.001 1.40 (1.03–1.90) 0.031
Contributing condition 1.12 (0.81–1.56) 0.49 1.00 (0.68–1.47) 0.99
Sexual orientation and gender
MSM 1 1
Heterosexual men 1.83 (1.39–2.41) 1.20 (0.83–1.73)
Women (all) 1.43 (1.02–2.00) \0.001 0.86 (0.57–1.30) 0.23
Site
London 1
Rome 1.60 (1.17–2.19) 0.013 1.85 (1.31–2.62)c \0.001
Copenhagen 1.01 (0.59–1.74)
Minsk 0.79 (0.37–1.69)
Non-white ethnicity 1.40 (1.06–1.85) 0.018 1.36 (0.95–1.97) 0.096
Migrant 1.13 (0.88–1.46) 0.34
Can meet basic needs 0.62 (0.48–0.81) \0.001 0.71 (0.54–0.94) 0.017
Recent psychoactive drug use 0.82 (0.59–1.13) 0.22
Lifetime IDU 0.99 (0.70–1.41) 0.96
Problem drinkingd 0.56 (0.37–0.83) 0.004 0.68 (0.46–1.00) 0.049
Depressive symptomse
None/minimal/mild 1 1
Moderate 1.08 (0.70–1.68) 1.04 (0.66–1.64)
Severe 1.49 (1.10–2.01) 0.033 1.53 (1.09–2.14) 0.049
Anxiety symptomse
None/mild 1
Moderate 1.56 (1.16–2.10)
Severe 1.21 (0.80–1.84) 0.012
CD4 count, cells/lL
[500 1
351–500 0.89 (0.66–1.21)
200–350 0.72 (0.47–1.11)
\200 1.12 (0.71–1.77) 0.40
Nadir CD4 count
[500 1
351–500 0.98 (0.67–1.44)
200–350 0.85 (0.58–1.24)
\200 1.05 (0.75–1.48) 0.65
Years since positive HIV test
Per ?5 years 1.10 (1.01–1.20) 0.037 1.09 (0.99–1.19) 0.090
VL and ART statuse
VL\50 copies/mL 1
Detectable VL on ART 0.96 (0.60–1.54)
Not on ART 1.10 (0.74–1.64) 0.87
Hepatitis C positive 0.89 (0.65–1.22) 0.47
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ideal healthy population, but in this respect the platform
fares no worse than many traditional neuropsychological
tests. The size of the control sample and its distribution
according to age, sex and education is adequate for the
purpose. Cogstate’s main advantage is its widespread usage
which allows comparison with other studies. Another
limitation is that our sampling strategy may have been
biased and led to over-recruitment of particular social
groups, patients with concerns about their neuropsycho-
logical health, or those with an interest in this field of
research. This study only partially achieves the objective of
eliciting risk factors relating to social and cultural differ-
ences. Our study sample was less diverse in ethnicity and
gender than we anticipated.
An unusual feature of our results was the effect of study
site, independent of measured confounders. Our sites dif-
fered not only linguistically and culturally but also in their
race and gender mix, clinical stage, and prevalence of
substance use; this is both a limitation and an interesting
finding. The effect of site could have been caused by a real
difference in characteristics of participants between HIV?
populations at the different sites, by unmeasured con-
founders, or by local selection biases or differences in
assessment technique. This has implications when com-
paring data from different locations in other studies. The
effects were present despite the fact that Cogstate is
designed to be culture-neutral and highly standardized.
There were differences between the Rome site and others
on several different neurocognitive tests, which is less
consistent with this being a problem of administration of
some part of the battery, although this cannot be ruled out.
In sensitivity analyses, we showed a similar pattern of risk
factors while accounting for site effects. Our study inclu-
ded a site from Eastern Europe, which is a relatively under-
researched region for the study of neurocognitive disorders
and HIV in general. We have endeavored to determine the
validity of the Cogstate testing platform in the region, by
adjusting for known confounders and also through
sensitivity analyses. It appeared that patients in Minsk were
slower on reaction time tasks but performed better on
verbal memory. It is unfortunate that our final sample from
Minsk was small and we hope that future studies can
explore these findings in this neglected region.
Several factors were found to be associated with NCI.
The effect of time since HIV diagnosis on the prevalence of
NCI, while weak in our adjusted analysis, has been
reported in the START study in a pre-treatment clinical
trial population with CD4 counts above 500 cells/lL [11].
This may reflect chronic neurotoxicity caused by HIV or
ART, similar to the effect of nadir CD4 count seen in other
patient populations [5, 33]. These observations concur with
the Antiretrovirals, Sexual Transmission Risk and Atti-
tudes (ASTRA) study, in which longer time diagnosed with
HIV was strongly associated with physical, psychological
and functional difficulties [34]. It is not possible, in this
study, to separate out the cohort effect of being diagnosed
prior to the development of effective ART in the 1990s,
and we note that time since HIV diagnosis is only a proxy
for time since infection.
Patients with limited economic means, fewer years’
education, and of minority ethnicity were more likely to
have NCI, again in keeping with previous work
[4, 10, 32, 35–37]. An association between NCI and edu-
cation was observed despite normalization of Z-scores by
this factor. This is in keeping with the US Women’s
Interagency HIV Study, in which there was a greater
adverse effect of low reading level in HIV? than in HIV-
negative women [10]. Residual differences associated with
educational attainment and social group may indicate that
cognitive reserve is important in HIV-associated NCI [38],
or they may relate to inadequate standardization of the
normative data. Comorbid conditions have also been
identified in other studies as risk factors for NCI in HIV
positive patients [8, 35, 36]. Age exerted an effect on
several different tasks, particularly speed-based tests,
where the primary measure was a latency period in
Table 3 continued
Variable PR (CI), partially-adjustedb P PR (CI), fully-adjustedb P
Previous AIDS 0.96 (0.68–1.33) 0.79
ART antiretroviral therapy, CI confidence interval, IDU intravenous drug use, MSM men who have sex with men, PR prevalence ratio, VL viral
load
a Neurocognitive impairment was defined as Z B -1 in at least 2 out of 5 cognitive domains
b The partially-adjusted model included age, sexual orientation, education, and confounding and contributing conditions. The fully-adjusted
model included these variables, and all other variables with p B 0.1 in the partially-adjusted model
c In the multivariable model, all sites other than Rome were combined into a single reference group
d Problem drinking was defined by the modified (two-question) AUDIT-C questionnaire: a positive score was C5 points for men or C4 points for
women
e Excludes missing data
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milliseconds, and those involving verbal memory. Severe
depression also affected timed tasks and unfortunately
there are no standard adjustments available for the
assessment of patients with mood disorders.
The paradoxical effect of alcohol in this study, where
participants with problem drinking were less likely to have
NCI, is at odds with the well-established harmful neuro-
logical effects of alcohol. We found a similar effect when
the results were re-analyzed with the CAGE questionnaire
as a means of measuring problem drinking, and the effect
did not disappear after adjustment for potential con-
founders. Selection bias must be considered as a possible
explanation. Information bias in our recording of alcohol
use could arise from perceived social desirability, or
because the modified AUDIT-C fails to capture cumulative
lifetime alcohol consumption. It is notable that alcohol use
behavior differed markedly between sites, with the UK and
Denmark showing much higher rates of problem drinking
than Italy and Belarus.
In conclusion, impaired NP performance was frequently
present among HIV ? patients, although most patients did
not report decline in daily function or they had con-
founding comorbidities to explain their impairment. The
discordance between subjective and objective impairment
of cognitive function requires further study. A constella-
tion of factors was associated with poorer test scores,
including education, socioeconomic circumstances and
time since HIV diagnosis. Important outstanding questions
in this field relate to the validity of neuropsychological
tests and the Frascati criteria when used across linguisti-
cally and culturally diverse groups of HIV? people.
Interventions to prevent NCI in PLWH include earlier
diagnosis of HIV, earlier initiation of ART, addressing
cardiovascular risk factors, and identifying and treating
mental health disorders such as depression and substance
use. In future work, the CIPHER study will report how
our baseline observations predict longer-term changes in
neurocognitive function.
Table 4 Associations between selected factors and scores obtained on single neuropsychological tests where positive numbers suggest cognitive
impairment
Variable Detection speeda Identification speeda One-back speeda Maze learningb Maze recallb
Age (per ?10 years) 20 (8, 31) 18 (8, 28)d 18 (6, 29)c 3.8 (1.7, 5.9)d 0.7 (0.2, 1.2)
Site
London Reference Reference Reference Reference Reference
Rome 29 (-0, 58) 29 (-5, 53) 19 (-9, 47) 6.1 (1.0, 11.2) 0.5 (-0.8, 1.8)
Copenhagen 10 (-23, 42) 17 (-10, 44) 24 (-7, 55) -1.6 (-7.3, 4.2) -0.8 (-2.2, 0.6)
Minsk 106 (56, 156)d 54 (12, 96) 38(-10, 86) -1.1 (-7.8, 9.9) -0.4 (-2.6, 1.8)
Sexual orientation
MSM Reference Reference Reference Reference Reference
Heterosexual men -19 (-52, 15) 16 (-11, 44) -5 (-36, 27) 3.2 (-2.6, 9.1) 1.1 (-0.3, 2.6)
Women (all) 4 (-28, 35) 2 (-24, 28) 3 (-27, 33) 0.25 (-5.3, 5.8) 0.2 (-1.2, 1.6)
University education -7 (-27, 13) -2 (-19, 15) -9 (-28, 11) -3.2 (-6.7, 0.4) -1.0 (-1.9, -0.1)
Confounding condition -4 (-30, 23) 16 (-6, 38) 14 (-11, 39) 2.7 (-2.0, 7.3) 0.0 (-1.1, 1.2)
Contributing condition 2 (-26, 30) -3 (-26, 21) 0 (-26, 27) -2.1 (-7.0, 2.9) -0.9 (-2.1, 0.3)
Non-white ethnic group 40 (9, 72) 24 (-2, 50) 4 (-26, 34) 8.2 (2.7, 13.7)c 2.4 (1.0, 3.7)c
Cannot always meet basic needs -2 (-22, 18) -7 (-23, 10) -18 (-37, 1) -2.3 (-5.8, 1.2) -0.3 (1.2, 0.6)
Depression
None/mild Reference Reference Reference Reference Reference
Moderate 25 (-6, 55) 27 (2, 53) 13 (-16, 42) -1.5 (-6.9, 3.9) 0.1 (-1.3, 1.4)
Severe 56 (26, 86)d 44 (18, 69)c 51 (23, 80)c 0.4 (-5.0, 5.7) 0.9 (-0.5, 2.2)
Time since HIV positive (per year) 18 (4, 33) 7 (-6, 19) 8 (-6, 22) 1.0 (-1.6, 3.6) 0.8 (0.2, 1.5)
Recent recreational drug use -4 (-27, 19) -7 (-26, 12) -12 (-34, 10) -1.2 (-5.3, 2.8) 0.1 (-0.9, 1.1)
Problem drinking 10 (-12, 33) 8 (-11, 26) -0 (-21, 21) -3.5 (-7.4, -0.5) -1.2 (-2.2, -0.3)
Tests in this table yield a higher score with worse performance (longer latency or more errors). Associations are expressed as the size of effect on
the raw score (95% confidence interval)
a Speed tasks are measured in log10 (latency in milliseconds) 910
-3
b Maze-based tests of executive function are expressed as total number of errors
c P\ 0.005
d P\ 0.001
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Table 5 Associations between selected factors and scores obtained on single neuropsychological tests where negative numbers suggest cog-
nitive impairment
Variable One-back accuracya List learningb List recallb CFTb COWATb
Age (per ?10 years) 0.006 (-0.012, 0.024) -1.2d (-1.6, -0.7) -0.6d (-0.9, -0.4) -0.2 (-0.9, 0.5) 1.7 (0. 3, 3.2)
Site
London Reference Reference Reference Reference Reference
Rome -0.13d (-0.18, -0.09) -3.5d (-4.7, -2.3) -1.6d (-2.3, -1.0) -0.0 (-1.7, 1.7) 1.3 (-2.2, 4.8)
Copenhagen -0.011 (-0.06, 0.04) -0.8 (-2.1, 0.5) -0.8 (-1.4, -0.1) -0.2 (-2.1, 1.7) -7.8d (-11.7, -3.8)
Minsk 0.02 (-0.06, 0.09) 1.0 (-1.0, 3.0) 0.6 (-0.5, 1.7) 3.9 (0.9, 6.8) -2.0 (-8.0, 4.1)
Sexual orientation
MSM Reference Reference Reference Reference Reference
Heterosexual men -0.06 (-0.11, -0.01) -2.0c (-3.3, -0.7) -0.5 (-1.2, 0.2) -2.1 (-4.1, -0.1) -5.4 (-9.4, -1.3)
Women (all) 0.00 (-0.05, 0.05) -0.1 (-1.4, 1.1) 0.4 (-0.3, 1.1) -0.6 (-2.5, 1.2) 1.1 (-2.7, 4.9)
University education 0.008 (-0.02, 0.04) 0.7 (-0.1, 1.5) 0.3 (-0.1, 0.7) 1.5 (0.3, 2.7) 3.3 (0.9, 5.8)
Confounding condition 0.001 (-0.04, 0.04) -0.4 (-1.5, 0.6) -0.5 (-1.0, 0.1) -2.1 (-3.6, -0.5) -2.3 (-5.5, 0.9)
Contributing condition 0.01 (-0.03, 0.05) 0.5 (-0.6, 1.6) 0.1 (-0.5, 0.7) -0.5 (-2.1, 1.2) 2.2 (-1.2, 5.6)
Non-white ethnic group 0.02 (-0.03, 0.07) -1.6 (-2.8, -0.3) -0.6 (-1.3, 0.0) -2.1 (-4.0, -0.3) -1.3 (-5.1, 2.5)
Cannot always meet basic
needs
-0.01 (-0.04, 0.02) -1.0 (-1.9, -0.3) -0.4 (-0.9, 0.0) -2.2 (-3.4, -1.0)d -4.2 (-6.6, -1.8)d
Depression
None/mild Reference Reference Reference Reference Reference
Moderate -0.04 (-0.09, 0.00) -0.4 (-1.6, 0.8) -0.2 (-0.9, 0.5) 0.9 (-0.9, 2.7) -1.8 (-5.5, 2.0)
Severe -0.05 (-0.10, -0.01) -0.8(-2.0, 0.4) -0.7 (-1.4, -0.1) -0.1 (-1.8, 1.7) -1.4 (-5.0, 2.3)
Time since HIV positive
(per ?10 years)
-0.006 (-0.03, 0.02) -0.1 (-0.7, 0.4) -0.0 (-0.4, 0.3) 0.4 (-0.5, 1.3) 0.4 (-1.4, 2.2)
Recent recreational drug
use
-0.04 (-0.08, -0.01) -0.8 (-1.7, 0.1) -0.2 (-0.7, 0.3) 1.0 (-0.4, 2.4) 0.2 (-2.5, 3.0)
Problem drinking 0.04 (0.01, 0.08) 0.4 (-0.5, 1.3) 0.4 (-0.0, 0.9) 0.9 (-0.4, 2.2) 2.7 (-0.0, 5.4)
CFT category fluency test, COWAT controlled oral word association test
Tests in this table yield a higher score with better performance (better accuracy or more correct responses). Associations are expressed as effect
size (95% confidence interval)
a One-back accuracy is expressed as the arcsine transformation of the square root of the proportion of correct responses
b Verbal fluency tasks and list learning and recall tasks are expressed as total number of valid correct answers
c P\ 0.005
d P\ 0.001
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